Literature DB >> 33865977

Care Fragmentation and Mortality in Readmission after Surgery for Hepatopancreatobiliary and Gastric Cancer: A Patient-Level and Hospital-Level Analysis of the Healthcare Cost and Utilization Project Administrative Database.

David G Brauer1, Ningying Wu2, Matthew R Keller3, Sarah A Humble2, Ryan C Fields2, Chet W Hammill2, William G Hawkins2, Graham A Colditz2, Dominic E Sanford2.   

Abstract

BACKGROUND: Hepatopancreatobiliary (HPB) and gastric oncologic operations are frequently performed at referral centers. Postoperatively, many patients experience care fragmentation, including readmission to "outside hospitals" (OSH), which is associated with increased mortality. Little is known about patient-level and hospital-level variables associated with this mortality difference. STUDY
DESIGN: Patients undergoing HPB or gastric oncologic surgery were identified from select states within the Healthcare Cost and Utilization Project database (2006-2014). Follow-up was 90 days after discharge. Analyses used Kruskal-Wallis test, Youden index, and multilevel modeling at the hospital level.
RESULTS: There were 7,536 patients readmitted within 90 days of HPB or gastric oncologic surgery to 636 hospitals; 28% of readmissions (n = 2,123) were to an OSH, where 90-day readmission mortality was significantly higher: 8.0% vs 5.4% (p < 0.01). Patients readmitted to an OSH lived farther from the index surgical hospital (median 24 miles vs 10 miles; p < 0.01) and were readmitted later (median 25 days after discharge vs 12; p < 0.01). These variables were not associated with readmission mortality. Surgical complications managed at an OSH were associated with greater readmission mortality: 8.4% vs 5.7% (p < 0.01). Hospitals with <100 annual HPB and gastric operations for benign or malignant indications had higher readmission mortality (6.4% vs 4.7%, p = 0.01), although this was not significant after risk-adjustment (p = 0.226).
CONCLUSIONS: For readmissions after HPB and gastric oncologic surgery, travel distance and timing are major determinants of care fragmentation. However, these variables are not associated with mortality, nor is annual hospital surgical volume after risk-adjustment. This information could be used to determine safe sites of care for readmissions after HPB and gastric surgery. Further analysis is needed to explore the relationship between complications, the site of care, and readmission mortality.
Copyright © 2021 American College of Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 33865977      PMCID: PMC8790704          DOI: 10.1016/j.jamcollsurg.2021.03.017

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.532


  40 in total

1.  Index for rating diagnostic tests.

Authors:  W J YOUDEN
Journal:  Cancer       Date:  1950-01       Impact factor: 6.860

2.  Hospital volume and patient outcomes in hepato-pancreatico-biliary surgery: is assessing differences in mortality enough?

Authors:  Eric B Schneider; Aslam Ejaz; Gaya Spolverato; Kenzo Hirose; Martin A Makary; Christopher L Wolfgang; Nita Ahuja; Matthew Weiss; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2014-10-09       Impact factor: 3.452

3.  Extending Enhanced Recovery after Surgery Protocols to the Post-Discharge Setting: A Phone Call Intervention to Support Patients after Expedited Discharge after Pancreaticoduodenectomy.

Authors:  Rony Takchi; Gregory A Williams; David Brauer; Tina Stoentcheva; Crystal Wolf; Brooke Van Anne; Cheryl Woolsey; William G Hawkins
Journal:  Am Surg       Date:  2020-01-01       Impact factor: 1.002

4.  Hospital readmission by method of data collection.

Authors:  Elizabeth M Hechenbleikner; Martin A Makary; Daniel V Samarov; Jennifer L Bennett; Susan L Gearhart; Jonathan E Efron; Elizabeth C Wick
Journal:  J Am Coll Surg       Date:  2013-04-11       Impact factor: 6.113

5.  Simplified risk prediction indices do not accurately predict 30-day death or readmission after discharge following colorectal surgery.

Authors:  David G Brauer; Sarah A Lyons; Matthew R Keller; Matthew G Mutch; Graham A Colditz; Sean C Glasgow
Journal:  Surgery       Date:  2019-01-29       Impact factor: 3.982

6.  Hepatic resection in the United States: indications, outcomes, and hospital procedural volumes from a nationally representative database.

Authors:  Justin B Dimick; John A Cowan; James A Knol; Gilbert R Upchurch
Journal:  Arch Surg       Date:  2003-02

7.  Patient readmission and mortality after surgery for hepato-pancreato-biliary malignancies.

Authors:  Eric B Schneider; Omar Hyder; Christopher L Wolfgang; Kenzo Hirose; Michael A Choti; Martin A Makary; Joseph M Herman; John L Cameron; Timothy M Pawlik
Journal:  J Am Coll Surg       Date:  2012-08-24       Impact factor: 6.113

8.  Tracking early readmission after pancreatectomy to index and nonindex institutions: a more accurate assessment of readmission.

Authors:  Jeffrey J Tosoian; Caitlin W Hicks; John L Cameron; Vicente Valero; Frederic E Eckhauser; Kenzo Hirose; Martin A Makary; Timothy M Pawlik; Nita Ahuja; Matthew J Weiss; Christopher L Wolfgang
Journal:  JAMA Surg       Date:  2015-02       Impact factor: 14.766

9.  How Far Are Patients Willing to Travel for Gastrectomy?

Authors:  Donna Marie L Alvino; David C Chang; Joel T Adler; Abraham Noorbakhsh; Ginger Jin; John T Mullen
Journal:  Ann Surg       Date:  2017-06       Impact factor: 12.969

10.  A Study of Clinical Coding Accuracy in Surgery: Implications for the Use of Administrative Big Data for Outcomes Management.

Authors:  S A R Nouraei; A Hudovsky; A E Frampton; U Mufti; N B White; C G Wathen; G S Sandhu; A Darzi
Journal:  Ann Surg       Date:  2015-06       Impact factor: 12.969

View more
  1 in total

1.  Patterns and Impact of Fragmented Care in Stage II and III Gastric Cancer.

Authors:  Kristen E Rhodin; Vignesh Raman; Austin Eckhoff; Annie Liu; John Creasy; Daniel P Nussbaum; Dan G Blazer
Journal:  Ann Surg Oncol       Date:  2022-06-20       Impact factor: 4.339

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.